Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

VCEL vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VCEL
Vericel Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.86B
5Y Perf.+155.8%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$111.96B
5Y Perf.+49.4%

VCEL vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VCEL logoVCEL
SYK logoSYK
IndustryBiotechnologyMedical - Devices
Market Cap$1.86B$111.96B
Revenue (TTM)$276M$25.12B
Net Income (TTM)$17M$3.25B
Gross Margin74.4%63.5%
Operating Margin4.0%22.4%
Forward P/E84.6x19.5x
Total Debt$96M$14.86B
Cash & Equiv.$100M$4.01B

VCEL vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VCEL
SYK
StockMay 20May 26Return
Vericel Corporation (VCEL)100255.8+155.8%
Stryker Corporation (SYK)100149.4+49.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: VCEL vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Vericel Corporation is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
VCEL
Vericel Corporation
The Growth Play

VCEL is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 16.5%, EPS growth 60.0%, 3Y rev CAGR 18.9%
  • 12.8% 10Y total return vs SYK's 185.6%
  • Lower volatility, beta 1.47, Low D/E 27.1%, current ratio 5.03x
Best for: growth exposure and long-term compounding
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.

  • Dividend streak 34 yrs, beta 0.55, yield 1.1%
  • PEG 1.31 vs VCEL's 2.14
  • Beta 0.55, yield 1.1%, current ratio 1.89x
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthVCEL logoVCEL16.5% revenue growth vs SYK's 11.2%
ValueSYK logoSYKLower P/E (19.5x vs 84.6x), PEG 1.31 vs 2.14
Quality / MarginsSYK logoSYK12.9% margin vs VCEL's 6.0%
Stability / SafetySYK logoSYKBeta 0.55 vs VCEL's 1.47
DividendsSYK logoSYK1.1% yield; 34-year raise streak; the other pay no meaningful dividend
Momentum (1Y)VCEL logoVCEL-4.3% vs SYK's -21.7%
Efficiency (ROA)SYK logoSYK6.9% ROA vs VCEL's 3.4%, ROIC 11.4% vs 2.5%

VCEL vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VCELVericel Corporation
FY 2025
MACI Implants And Kits
100.0%$240M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

VCEL vs SYK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSYKLAGGINGVCEL

Income & Cash Flow (Last 12 Months)

SYK leads this category, winning 4 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 90.9x VCEL's $276M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to VCEL's 6.0%. On growth, VCEL holds the edge at +23.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
RevenueTrailing 12 months$276M$25.1B
EBITDAEarnings before interest/tax$3M$6.3B
Net IncomeAfter-tax profit$17M$3.2B
Free Cash FlowCash after capex$35M$4.3B
Gross MarginGross profit ÷ Revenue+74.4%+63.5%
Operating MarginEBIT ÷ Revenue+4.0%+22.4%
Net MarginNet income ÷ Revenue+6.0%+12.9%
FCF MarginFCF ÷ Revenue+12.7%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+23.3%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+21.1%+56.0%
SYK leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

SYK leads this category, winning 7 of 7 comparable metrics.

At 34.8x trailing earnings, SYK trades at a 70% valuation discount to VCEL's 114.9x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.34x vs VCEL's 2.91x — a lower PEG means you pay less per unit of expected earnings growth.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
Market CapShares × price$1.9B$112.0B
Enterprise ValueMkt cap + debt − cash$1.9B$122.8B
Trailing P/EPrice ÷ TTM EPS114.94x34.80x
Forward P/EPrice ÷ next-FY EPS est.84.65x19.49x
PEG RatioP/E ÷ EPS growth rate2.91x2.34x
EV / EBITDAEnterprise value multiple652.83x20.19x
Price / SalesMarket cap ÷ Revenue6.74x4.46x
Price / BookPrice ÷ Book value/share5.40x4.98x
Price / FCFMarket cap ÷ FCF35.87x26.14x
SYK leads this category, winning 7 of 7 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 5 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $5 for VCEL. VCEL carries lower financial leverage with a 0.27x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), VCEL scores 8/9 vs SYK's 6/9, reflecting strong financial health.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
ROE (TTM)Return on equity+4.7%+15.0%
ROA (TTM)Return on assets+3.4%+6.9%
ROICReturn on invested capital+2.5%+11.4%
ROCEReturn on capital employed+2.7%+13.0%
Piotroski ScoreFundamental quality 0–986
Debt / EquityFinancial leverage0.27x0.66x
Net DebtTotal debt minus cash-$4M$10.8B
Cash & Equiv.Liquid assets$100M$4.0B
Total DebtShort + long-term debt$96M$14.9B
Interest CoverageEBIT ÷ Interest expense-20.45x6.72x
SYK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

VCEL leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,108 today (with dividends reinvested), compared to $6,927 for VCEL. Over the past 12 months, VCEL leads with a -4.3% total return vs SYK's -21.7%. The 3-year compound annual growth rate (CAGR) favors VCEL at 3.7% vs SYK's 1.6% — a key indicator of consistent wealth creation.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
YTD ReturnYear-to-date+3.3%-15.8%
1-Year ReturnPast 12 months-4.3%-21.7%
3-Year ReturnCumulative with dividends+11.5%+4.8%
5-Year ReturnCumulative with dividends-30.7%+21.1%
10-Year ReturnCumulative with dividends+1282.7%+185.6%
CAGR (3Y)Annualised 3-year return+3.7%+1.6%
VCEL leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — VCEL and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than VCEL's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VCEL currently trades 80.0% from its 52-week high vs SYK's 72.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.47x0.55x
52-Week HighHighest price in past year$45.97$404.87
52-Week LowLowest price in past year$28.95$289.91
% of 52W HighCurrent price vs 52-week peak+80.0%+72.2%
RSI (14)Momentum oscillator 0–10058.325.4
Avg Volume (50D)Average daily shares traded615K2.0M
Evenly matched — VCEL and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates VCEL as "Buy" and SYK as "Buy". Consensus price targets imply 38.1% upside for SYK (target: $404) vs 19.6% for VCEL (target: $44). SYK is the only dividend payer here at 1.15% yield — a key consideration for income-focused portfolios.

MetricVCEL logoVCELVericel Corporati…SYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$44.00$403.69
# AnalystsCovering analysts1450
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises34
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

SYK leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). VCEL leads in 1 (Total Returns). 1 tied.

Best OverallStryker Corporation (SYK)Leads 3 of 6 categories
Loading custom metrics...

VCEL vs SYK: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is VCEL or SYK a better buy right now?

For growth investors, Vericel Corporation (VCEL) is the stronger pick with 16.

5% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Stryker Corporation (SYK) offers the better valuation at 34. 8x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate Vericel Corporation (VCEL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — VCEL or SYK?

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 34.

8x versus Vericel Corporation at 114. 9x. On forward P/E, Stryker Corporation is actually cheaper at 19. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 31x versus Vericel Corporation's 2. 14x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — VCEL or SYK?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

1%, compared to -30. 7% for Vericel Corporation (VCEL). Over 10 years, the gap is even starker: VCEL returned +1283% versus SYK's +185. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — VCEL or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Vericel Corporation's 1. 47β — meaning VCEL is approximately 169% more volatile than SYK relative to the S&P 500. On balance sheet safety, Vericel Corporation (VCEL) carries a lower debt/equity ratio of 27% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — VCEL or SYK?

By revenue growth (latest reported year), Vericel Corporation (VCEL) is pulling ahead at 16.

5% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Vericel Corporation grew EPS 60. 0% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, VCEL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — VCEL or SYK?

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus 6. 0% for Vericel Corporation — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 4. 0% for VCEL. At the gross margin level — before operating expenses — VCEL leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is VCEL or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 31x versus Vericel Corporation's 2. 14x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 5x forward P/E versus 84. 6x for Vericel Corporation — 65. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 38. 1% to $403. 69.

08

Which pays a better dividend — VCEL or SYK?

In this comparison, SYK (1.

1% yield) pays a dividend. VCEL does not pay a meaningful dividend and should not be held primarily for income.

09

Is VCEL or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +185. 6% 10Y return). Both have compounded well over 10 years (SYK: +185. 6%, VCEL: +1283%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between VCEL and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VCEL is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while VCEL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

VCEL

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 5%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform VCEL and SYK on the metrics below

Revenue Growth>
%
(VCEL: 23.3% · SYK: 11.4%)
Net Margin>
%
(VCEL: 6.0% · SYK: 12.9%)
P/E Ratio<
x
(VCEL: 114.9x · SYK: 34.8x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.